...
首页> 外文期刊>Transactions of the Royal Society of Tropical Medicine and Hygiene >Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru
【24h】

Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru

机译:支持秘鲁逐步淘汰II类治疗方案的其他证据

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The effectiveness of the World Health Organization's (WHO) treatment category II regimen for tuberculosis in 124 patients was compared to that of 1147 patients receiving treatment category I in Lima, Peru following WHO's guidelines. Drug susceptibility test was available for 85% of patients. Prevalence of multi drug resistance and streptomycin resistance were 5.1% and 20.7%, respectively. Overall cure rate for regimen II was lower than that of regimen I: 67.8% (95% CI: 58.9-75.6.) vs 77.8% (95% CI: 75.3-80.2), p = 0.014. Multi-drug resistance exerted a profound effect on cure rates in both regimens. Our results support the phasing-out of treatment category II regimen in Peru.
机译:按照世界卫生组织的指南,将世界卫生组织(WHO)的II类肺结核治疗方案对124例患者的有效性与在秘鲁利马接受1类治疗的1147例患者的有效性进行了比较。 85%的患者可以进行药敏试验。多重耐药和链霉素耐药的患病率分别为5.1%和20.7%。方案II的总治愈率低于方案I:67.8%(95%CI:58.9-75.6。)vs 77.8%(95%CI:75.3-80.2),p = 0.014。在两种方案中,多药耐药性均对治愈率产生深远影响。我们的研究结果支持在秘鲁逐步淘汰II类治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号